Multi-Ingredient Ophthalmic Composition for Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular surface diseases like dry eye syndrome are often insufficient or too expensive, and existing formulations fail to provide adequate relief for many patients, leading to discomfort and visual impairment.
Innovation Solution
A pharmaceutical composition comprising mycophenolic acid, tacrolimus, cyclosporine, corticosteroids, albumin, plasma, platelet-rich plasma, serum, glycosaminoglycans, and lubricating agents, along with a carrier such as de-ionized water or balanced salt solution, is developed to treat, prevent, and alleviate ocular surface diseases, including dry eye syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing artificial tears and treatment products are used, then some relief may be provided in some cases, but they are insufficient or too expensive for many patients
Solution Approach 1:
The patent combines multiple active ingredients (cyclosporine, corticosteroid, glycosaminoglycan, and lubricating agent) into a single ophthalmic composition. This merging of therapeutic agents addresses the insufficiency of single-ingredient treatments while providing comprehensive relief for ocular surface disease and dry eye syndrome at a cost-effective price point.
2Adaptability or versatility
If multiple separate treatment products are used to address different aspects of ocular surface disease, then comprehensive coverage may be achieved, but treatment complexity and cost increase
Solution Approach 1:
The patent integrates four distinct therapeutic agents into one unified ophthalmic composition: cyclosporine (0.05-5.0% w/v) for immunomodulation, corticosteroid (0.001-0.5% w/v) for anti-inflammatory effect, glycosaminoglycan (0.01-5.0% w/v) for corneal protection, and lubricating agent for symptom relief. This single multi-ingredient product replaces what would otherwise require multiple separate treatments, reducing complexity while maintaining comprehensive coverage.
3Ease of operation
If conventional treatments are used, then some patients may experience relief, but many patients continue to experience discomfort and visual disturbance
Solution Approach 1:
The combination formulation addresses multiple pathophysiological mechanisms simultaneously: cyclosporine reduces inflammation, corticosteroid provides rapid anti-inflammatory relief, glycosaminoglycan protects the corneal surface, and lubricating agents alleviate dryness. This multi-target approach ensures consistent symptom relief and improved patient comfort across diverse dry eye disease presentations.
Data Source
AI summary
Pharmaceutical compositions are described, the compositions comprising therapeutically effective quantities of compounds (such as mycophenolic acid or cyclosporine) that are capable of treating, preventing, and/or or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.